Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Minhang Maternal and Children Health Care Hospital | OTHER |
| School of Public Health，Fudan University | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This prospective cohort study aims to investigate the association between prenatal blood levels of Emerging Contaminants and the five-year incidence of atopic dermatitis (AD) in offspring.
This prospective birth cohort study, conducted within the Shanghai prenatal population, involves the collection of maternal blood samples during gestation to directly measure the biological exposure levels of Emerging Contaminants, including Per- and Polyfluoroalkyl Substances (PFAS), Organophosphate Flame Retardants (OPFRs), and Microplastics. Serum and whole blood levels of these contaminants are evaluated during pregnancy at 12-14, 22-26, and 31-34 gestational weeks. Subsequently, the study assesses skin barrier function in infants at 24-48 hours, 42 days, and 6 months of age. During a five-year period, the occurrence of atopic dermatitis (AD) in offspring is assessed. The objectives of this cohort study are twofold: (1) to elucidate the relationship between maternal exposure to Emerging Contaminants and the development of AD in offspring, and (2) to evaluate the impact of such exposure on the skin barrier function of infants. This research aims to provide substantial evidence for the prevention of AD, offering a unique and meaningful approach to mitigating the incidence of AD.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| participants from birth cohort with AD | The association between maternal whole blood and serum levels of Emerging Contaminants (ECs) including Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics during pregnancy and the incidence of atopic dermatitis in their offspring. |
| |
| participants from birth cohort without AD | The association between maternal whole blood and serum levels of Emerging Contaminants (ECs) including Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics during pregnancy and the reduced incidence of atopic dermatitis in their offspring. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gestational Exposure to Emerging Contaminants (ECs) | Other | Levels of Emerging Contaminants (ECs), such as Per- and Polyfluoroalkyl Substances (PFASs), Organophosphate Flame Retardants (OPFRs), and Microplastics, are assessed in maternal blood and umbilical cord blood during gestation. |
| Measure | Description | Time Frame |
|---|---|---|
| atopic dermatitis: Infant atopic dermatitis incidence | Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms. | at 1 year old |
| Measure | Description | Time Frame |
|---|---|---|
| atopic dermatitis | Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms. | incidence of AD during 6 months after birth |
| atopic dermatitis |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The research subjects come from the established MKNFOAD birth cohort (NCT 02889081), with on-site inclusion at the early pregnancy outpatient clinic of Minhang Maternal and Child Health Hospital.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ying Ye, MD,PhD | Children's Hospital of Fudan University Shanghai, China, 201102 | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children Hospital of Fudan University | Shanghai | Shanghai Municipality | 201102 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30428139 | Background | Lowe AJ, Dharmage SC, Abramson MJ, Vijayasarathy S, Erbas B, Mueller JF, Lodge CJ. Cord-serum per- and poly-fluoroalkyl substances and atopy and eczema at 12-months. Allergy. 2019 Apr;74(4):812-815. doi: 10.1111/all.13669. Epub 2018 Dec 4. No abstract available. | |
| 29343261 | Background | Chen Q, Huang R, Hua L, Guo Y, Huang L, Zhao Y, Wang X, Zhang J. Prenatal exposure to perfluoroalkyl and polyfluoroalkyl substances and childhood atopic dermatitis: a prospective birth cohort study. Environ Health. 2018 Jan 17;17(1):8. doi: 10.1186/s12940-018-0352-7. |
Not provided
Not provided
There is not a plan to make IPD available.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003876 | Dermatitis, Atopic |
| ID | Term |
|---|---|
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003872 | Dermatitis |
Not provided
Not provided
Not provided
Not provided
Not provided
All serum, whole blood, and DNA samples are stored in a -80°C freezer.
|
|
Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms. |
| incidence of AD at the age of two. |
| atopic dermatitis | Disease diagnosis according to the criteria of Williams. Skin status was examined via onsite interview by pediatric dermatologists. Parents consulted or visited a dermatologist once their baby developed any skin symptoms. | incidence of AD at the age of five. |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at early pregnancy | Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS | 12-14 gestational weeks |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at mid pregnancy | Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS | 22-26 gestational weeks |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at late pregnancy | Maternal whole blood levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS | 34-36 gestational weeks |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at first trimester | Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS | 12-14 gestational weeks |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at second trimester | Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS | 22-26 gestational weeks |
| prenatal exposure to Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) at third trimester | Maternal serum levels of Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) comprising 15 variants: PFPeA, PFHxA, PFHpA, PFOA, PFNA, PFDA, PFUnDA, PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS | 34-36 gestational weeks |
| Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) in Umbilical cord whole blood | Umbilical cord whole blood levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS | at delivery |
| Umbilical cord serum Perfluoroalkyl and Polyfluoroalkyl Substances (PFASs) | Umbilical cord serum levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS | at delivery. |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at early pregnancy | Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP | 12-14 gestational weeks |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at mid pregnancy | Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP | 22-26 gestational weeks |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at late pregnancy | Maternal whole blood levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP | 34-36 gestational weeks |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at first trimester | Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP | 12-14 gestational weeks |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at second trimester | Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP | 22-26 gestational weeks |
| prenatal exposure to Organophosphate Flame Retardants (OPFRs) at third trimester | Maternal serum levels of Organophosphate Flame Retardants (OPFRs) comprising 9 variants: TEP、TBP、TBEP/TBOEP、TPrP、TCEP、TCPP/TCIPP、TDCPP/TDCIPP、TDBP/TDBPP、TPhP/TPHP | 34-36 gestational weeks |
| Organophosphate Flame Retardants (OPFRs) in Umbilical cord whole blood | Umbilical cord whole blood levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS | at delivery |
| Umbilical cord serum Organophosphate Flame Retardants (OPFRs) | Umbilical cord serum levels of PFDoDA, PFTrDA, PFHpDA, PFBS, PFPeS, PFHxS, PFOS, and PFDS | at delivery |
| Infant skin barrier function (Transepidermal Water Loss, TEWL） | TEWL will be evaluated by the device of Multi Probe Adapter 4. | infant 24-48 hours |
| Infant skin barrier function (Transepidermal Water Loss, TEWL） | TEWL will be evaluated by the device of Multi Probe Adapter 4. | infant 42 days old |
| Infant skin barrier function (Transepidermal Water Loss, TEWL） | TEWL will be evaluated by the device of Multi Probe Adapter 4. | infant 6 months old |
| Infant skin barrier function (Stratum corneum hydration, SCH) | SCH will be evaluated by the device of Multi Probe Adapter 4. | infant 24-48 hours |
| Infant skin barrier function (Stratum corneum hydration, SCH) | SCH will be evaluated by the device of Multi Probe Adapter 4. | infant 42 days old |
| Infant skin barrier function (Stratum corneum hydration, SCH) | SCH will be evaluated by the device of Multi Probe Adapter 4. | infant 6 months old |
| Infant skin barrier function (sebum content) | Sebum content will be evaluated by the device of Multi Probe Adapter 4. | infant 24-48 hours |
| Infant skin barrier function (sebum content) | Sebum content will be evaluated by the device of Multi Probe Adapter 4. | infant 42 days old |
| Infant skin barrier function (sebum content) | Sebum content will be evaluated by the device of Multi Probe Adapter 4. | infant 6 months old |
| Infant skin barrier function (skin surface pH) | Skin pH will be evaluated by the device of Multi Probe Adapter 4. | infant 24-48 hours |
| Infant skin barrier function (skin surface pH) | Skin pH will be evaluated by the device of Multi Probe Adapter 4. | infant 42 days old |
| Infant skin barrier function (skin surface pH) | Skin pH will be evaluated by the device of Multi Probe Adapter 4. | infant 6 months old |
| prenatal exposure to Microplastics at early pregnancy | Maternal whole blood levels of Microplastics | 12-14 gestational weeks |
| prenatal exposure to Microplastics at mid pregnancy | Maternal whole blood levels of Microplastics | 22-26 gestational weeks |
| prenatal exposure to Microplastics at late pregnancy | Maternal whole blood levels of Microplastics | 34-36 gestational weeks |
| prenatal exposure to Microplastics at first trimester | Maternal serum levels of Microplastics | 12-14 gestational weeks |
| prenatal exposure to Microplastics at second trimester | Maternal serum levels of Microplastics | 22-26 gestational weeks |
| prenatal exposure to Microplastics at third trimester | Maternal serum levels of Microplastics | 34-36 gestational weeks |
| Microplastics in Umbilical cord whole blood | Umbilical cord whole blood levels of Microplastics | at delivery. |
| Umbilical cord serum Microplastics | Umbilical cord serum levels of Microplastics | at delivery. |
| Allergic rhinitis | An inquiry into the patient's medical history and electronic medical record | incidence of allergic rhinitis at the age of five. |
| Asthma | An inquiry into the patient's medical history and electronic medical record | incidence of asthma at the age of five. |
| Infantile hemangioma | Diagnosed by dermatologists | incidence of Infantile hemangioma at 1 year old |
| 24486970 | Background | Okada E, Sasaki S, Kashino I, Matsuura H, Miyashita C, Kobayashi S, Itoh K, Ikeno T, Tamakoshi A, Kishi R. Prenatal exposure to perfluoroalkyl acids and allergic diseases in early childhood. Environ Int. 2014 Apr;65:127-34. doi: 10.1016/j.envint.2014.01.007. Epub 2014 Jan 29. |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |